INTRODUCTION
Chitosan has wide industrial applications such as lubricant, disintegrant, thickening, stabilising and suspending agent in pharmaceutical, textile and paper industries [1] . It is also a chelating agent for the removal of harmful metals in industrial and nuclear wastes, and a support for ion exchange, chelation and affinity chromatography [2] . The principal industrial source of chitin is shells of shrimp, lobster and crab.
Chitin and chitosan are distinguished by their solubility profile. Chitosan has favourable biological properties such as biodegradability, biocompatibility and non-toxicity. Chitosan was found to improve the fluidity of powder mixtures [3] and has satisfactory mucoadhesive property and good application potential [4] . Chitosan has antitumour activity, and hence chitosan microspheres bearing antineoplastic agents could be a promising carrier for cancer treatment [5] . It also holds immense promise for ophthalmic delivery [6] .
The pH-dependant solubility of chitosan is a function of the amino groups in the molecule and is a drawback for oral delivery in that chitosan microspheres formed by electrostatic interaction between a polyion and counterions become unstable in gastric fluid. This problem can be countered by irreversible chemical crosslinking. It has been demonstrated that drug diffusion from chitosan microspheres can be controlled by crosslinking with a dialdehyde such as glutaraldehyde [7] .
Famotidine is a H 2 receptor antagonist. It is widely prescribed in gastric and duodenal ulcers, Zollinger-Ellison syndrome and gastro esophageal reflux disease [8] . H 2 receptor antagonists not only inhibit gastric secretion induced by histamine, gastrin and cholinergic stimulation, they also promote healing of duodenal ulcers [9] . H 2 antihistamines, such as famotidine, have achieved clinical success with regard to the indications highlighted above. They block more than 90 % of nocturnal acid and 60 -70 % of daytime secretion. The relative potency of famotidine is also high when compared to other H 2 -antihistamines. The recommended dose for duodenal, gastric ulcers, reflux esophagitis, NSAID ulcers and ZollingerEllison syndrome is 20 -40 mg twice daily. It has been reported that the oral treatment of gastric disorders with H 2 antagonist, such as famotidine and ranitidine, when used in combination with antacids, promotes local delivery of these drugs to the receptor of parietal cell wall. Local delivery also increases stomach wall receptor site bioavailability and increases efficacy of drugs to reduce acid secretion. This principle may be applied for improving systemic as well as local delivery of famotidine, thereby efficiently reducing gastric acid secretion [10] .
Based on the foregoing, it would be useful to develop a formulation that deliver famotidine to sites in the stomach and thus enhance the effectiveness of the drug as well as provide sustained action. Hence, the objective of this work was to develop biodegradable microspheres of famotidine using chitosan for sustained release and site-specific delivery to the stomach. 
EXPERIMENTAL

Preparation of famotidine-loaded chitosan microspheres
Famotidine-containing chitosan microspheres were prepared at various drug: polymer ratios using a simple emulsion technique. A gel (6g) was prepared using chitosan (4 %) in 5 % aqueous acetic acid containing 2 % NaCl and the drug was added to it in varying drug:polymer ratios. The mixture was dispersed in a mixture of 35 ml liquid paraffin and 25 ml of petroleum ether containing 0.85 g of sorbitan sesquioleate in a 100 ml round bottom flask at room temperature [11] . The dispersion was stirred using stainless steel half moon-shaped paddle stirrer at 2000 rpm for 5 min and then 10ml of glutaraldehyde saturated toluene (GST), prepared according to the method of Patel et al [12] , was introduced into the flask while stirring. At the end of 30 min, glutaraldehyde (25 %v/v, aqueous) was added and stirring continued. In preliminary trial batches, the volume of the crosslinking agent (glutaraldehyde saturated in toluene) and crosslinking time were varied from 0.5 -15 ml and 1 -3 h, respectively. The stirrer speed was also varied from 1500 -3000 rpm. Stirring was continued for a total duration of 90min, at the end of which the hardened microspheres were filtered, washed several times, first with petroleum, then with acetone, 5% solution of sodium metabisulphate, and finally with water. The microspheres thus obtained were dried overnight in oven at 60 ºC and stored in a desiccator.
Determination of loading efficiency
Famotidine drug content in the preparation was determined by extracting the drug from the microspheres with 0.1M HCl. In this method, the microspheres (50 mg) were stirred in 50ml of 0.1M HCl until dissolved; it was filtered through a Millipore filter and the drug content determined, after suitable dilution, at 265 nm by spectrophotometry (Perkin Elmer-Lambda 25). The loading efficiency (L) of the microspheres was calculated according to Eq 1 [13] .
L (%) = (Q m /W m ) x 100 …………..……… (1) where W m is the weight of the microspheres and Q m is the amount of drug present in of the microspheres.
Entrapment efficiency
Fifty milligrams of accurately weighed microspheres were crushed in a glass mortar with a pestle and suspended in 10 ml of 0.1M HCl at pH 2. Twenty four hours later, the solution was filtered and the filtrate analysed for drug content as described for loading efficiency. Drug entrapment (E) was calculated using Eq 2 [12]. E (%) = W/T x 100 ………………………… (2) where W is the actual drug content of the microspheres while T is the theoretical content of the drug.
Particle size analysis and characterization of surface morphology
The size distribution of the microspheres in terms of their average diameter (d avg ) was determined by optical microscopy (CosLab). Scanning electron microscopy (SEM, Hitachi S-520) was performed to characterize the surface morphology of the microspheres. was All determinations were carried out in triplicate.
Fourier transform infrared (FT-IR) spectroscopy
FT-IR spectra of chitosan, famotidine and drug-loaded microspheres were recorded on a PerkinElmer (Spectrum R-X1) instrument using KBr disc in the range of 4000 -400 cm -1 in order to assess structural changes that could have occurred in the drug or polymer as a result of microsphere formulation.
Differential scanning calorimetry (DSC)
As DSC is a useful tool to monitor the effect of additives on the structural behavior of a material, this technique was used to obtain information about the physicochemical interaction the microsphere material and the drug [14] . Differential scanning calorimetry (DSC) of famotidine, blank microspheres, and drug loaded microspheres was performed with a DSC facility (model 821e, Mettler Toledo). Measurements were performed over a temperature range of 20 to 240 ºC at a heating rate of 10 ºC/min.
In vitro release study
In vitro release study on the microspheres (50 mg) was carried out in 50 ml of 0.1M HCl (pH 2) in a bottle at 37 ºC for the first two hours to simulate gastric conditions, and then in 50 ml of phosphate buffer (pH 6.8). The bottle was clamped in the orbital shaker (Remi) and agitated at 50 rpm. Samples (5ml) were collected at predetermined time intervals, for up to 24 h, for analysis. The medium was replenished with an equal volume of the dissolution medium after each sampling. The samples were analysed with a UV spectrophotometer (Perkin ElmerLambda 25) at 265 nm. All determinations were in triplicate
Statistical analysis
Statistical analysis was performed with Graph Pad Instat 3 software. All the tests were run in triplicate (n = 3). Experimental results were expressed as mean ± SD, and analyzed by one-way ANOVA for drug release data. Statistical significance was set at p < 0.05.
RESULTS
Preparation of microspheres
Following preliminary trials, 10 ml of glutaraldehyde saturated in toluene (GST), stirring speed of 2000 rpm and crosslinking time of 3h were adopted as processing factors for the preparation of the microspheres evaluated in this work. Table 1 shows that drug loading efficiency increased with increasing in the proportion of the polymer relative to the drug. Variation in drug : polymer ratio from 1:1 to 1:3 produced a drug loading efficiency of 15 ± 2 and 23 ± 3 % w/w. Further increase in polymer concentration showed slight reduction in the drug loading efficiency. (Table 1) Similarly, the entrapment efficiency of the microspheres also increased with increase in the proportion of the polymer relative to the drug, giving entrapment values of 30 ± 3 % w/w to 75 ± 5 %w/w for drug polymer ratios of 1:1 and 1:4, respectively. However, further increase in the proportion of the polymer resulted in a decrease in entrapment efficiency.
Drug-loading and entrapment efficiency
Particle size
As Table 1 shows, the mean particle size (diameter) of the microspheres increased with increase in the proportion of polymer relative to that of drug, with 42 % of the particles below 75 µm, 35 % in the range 75 -150 µm and 33 % in the range 150 -300 µm. When the stirring speed was lowered to 1500 rpm, the proportion of large microspheres (150 -300 µm range) increased. On the other hand, increase in stirring speed beyond 3000 rpm lowered particle size.
Scanning electron microscopy
The SEMs of the microspheres in Fig 1 indicate that they were fairly smooth and spherical in shape with an apparently homogenous surface. 
FTIR spectra
The FTIR spectra of chitosan, famotidine and famotidine-loaded chitosan microspheres are shown in 
Differential scanning calorimetry (DSC)
The thermograms of chitosan, famotidine drug and famotidine loaded chitosan microspheres are shown in Fig 3. The thermogram of chitosan showed a broad peak at 58 ºC which is attributed to water loss due to evaporation of absorbed water. No degradation DSC was observed for chitosan which would normally have occurred at 280 ºC [15, 16] . Famotidine thermogram showed a sharp endothermic peak at 158 ºC which corresponds to its melting point which is usually in the range 157-160 ºC. This peak was absent in the thermogram for the drugloaded chitosan microspheres.
In vitro release
The drug release data for the microspheres are shown in ) in order to ascertain the drug release mechanism, a linear relationship was observed with a regression coefficient close to 1 (r 2 = 0.993). 
DISCUSSION
Chitosan was selected as a polymer for the preparation of microspheres owing to its biodegradable, antiulcer, mucoadhesive properties as well as the possibility that it may offer synergism in the treatment of ulcer.
Famotidine microsphere production method was premised partly on the poor solubility of chitosan in water. Addition of acid improves the polymer's solubility as a result of the protonation of the amino groups. Its solubility is also dependent on other anions present in the solution. 
Drug release
When the volume of glutaraldehyde used in the microsphere preparation was increased to 15 ml, drug release decreased. This is because increase in glutaraldehyde concentration yielded highly crosslinked spheres with high density and reduced diffusion pathways. Increase in stirring speed beyond 3000 rpm has decreased particle size to as small as 10 µm thus resulting in faster drug release due to the increased surface area in contact with the dissolution medium. Increase in the crosslinking time favoured controlled release of drug from the microspheres. This is also due to the hardening of the spheres as a result of longer crosslinking time.
Drug-loading and entrapment efficiency
Several factors affect the entrapment efficiency of drugs in chitosan microspheres, e.g., nature of drug, chitosan concentration, drug polymer ratio, stirring speed, etc [18], At higher polymer concentrations, chitosan forms a highly viscous solution which is very difficult to process.
The increase in drug-loading and entrapment efficiency with increase in the polymer content of the microspheres can be attributed to the fact that at higher polymer concentrations, chitosan viscosity leading to a less diffuse matrix structure that hinders drug escape from the microsphere core. However, excessively high plymer content would hinder homogeneous distribution of the added crosslinking agent (glutaraldehyde) leading to the formation of larger particles with reduced drug content and entrapment efficiency.
Microsphere size
Mean particle size increased with increase in polymer content of the microspheres. It seems that when polymer content increased, a more viscous internal phase manifested during the emulsification process, and was poorly dispersed in the external phase. The result is the formation of large microspheres.
Compatibility issues
FTIR and DSC results obtained indicate that there were no interactions between famotidine, chitosan and the other ingredients used in the formulation, thus suggesting that the formulations would be stable. The absence of thermogram for the drug in the drug-loaded microsphere indicates that the drug was molecularly dispersed in the polymer matrix as a solid solution.
Optimum famotidine formulation
The in vitro release profiles of F1, F2 and F3 depended mainly on drug entrapment efficiency. Although the polymer content of F3 was relatively high, it also showed a high cumulative drug release due to its high drug entrapment. Thereby the increase in drug release was in the order of F1< F2< F3. While drug entrapment in F4 was higher than in F3, it, however, showed lower drug release due to its higher polymer concentration. In F5 both lower entrapment efficiency and higher polymer concentration and these might have led to a marked reduction in drug release. Thus, F3 (drug polymer ratio, 1:3) with a rapid burst release of 26.9 % in 2 h (due probably to a relatively high amount of drug entrapped near the surface of the microsphere) [19] , and overall (sustained) release of 85.6 % in 24 h that fitted well into Higuchi kinetic release model, can be considered, amongst all the formulations evaluated, to be the most suitable formulation in terms of reduction in frequency of administration of famotidine microsphere formulation and, thus has the potential to improve patient compliance.
CONCLUSION
The famotidine formulations developed in this study showed some potential for controlled delivery of famotidine and hence improved patient compliance. However, it would be necessary to undertake further studies, including bioavailability, in animal models with a view to determining if there is in vitroin vivo correlation.
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